Treating Alcoholism: Human Laboratory Studies of Quetiapine and Naltrexone

2012 ◽  
Author(s):  
Spencer Bujarski ◽  
Lara A. Ray
Keyword(s):  
Laboratory Studies ◽  
Human Laboratory

scholarly journals Translational dynamics of alcohol tolerance of preclinical models and human laboratory studies.

2020 ◽  
Vol 28 (4) ◽  
pp. 417-425
Author(s):  
Carolina L. Haass-Koffler ◽  
Nazzareno Cannella ◽  
Roberto Ciccocioppo
Keyword(s):  
Alcohol Tolerance ◽  
Laboratory Studies ◽  
Preclinical Models ◽  
Human Laboratory

scholarly journals Alcohol Tolerance in Human Laboratory Studies for Development of Medications to treat Alcohol Use Disorder

2020 ◽  
Vol 55 (2) ◽  
pp. 129-135
Author(s):  
Carolina L Haass-Koffler ◽  
Roberta Perciballi
Keyword(s):  
Alcohol Use ◽  
Alcohol Use Disorder ◽  
Motor Impairment ◽  
Alcohol Tolerance ◽  
Subjective Response ◽  
Laboratory Studies ◽  
Phenotypic Profile ◽  
Additional Information ◽  
Research Opportunity ◽  
Human Laboratory

Abstract Aims Human laboratory studies have contributed extensively in the research and development of novel medications to treat alcohol use disorder (AUD). Alcohol tolerance may represent one additional variable that can be utilized to expand the understanding of the AUD wide phenotypic profile and provide support to the medication development process. Tolerance is characterized as an individual’s subjective response to alcohol and has been recognized as a predictor of AUD progression. Tolerance can be evaluated both by self-reported response (e.g. assessments) and objective measurements (e.g. motor impairment); as such, it represents an exploitable variable in the field of alcohol research. Methods This Narrative Review focuses on the use of alcohol tolerance, specifically within alcohol laboratory studies, for medication development. It seeks to identify a research gap and a research opportunity in clinical studies to evaluate biobehavioral responses captured in order to develop medications to treat AUD. Results Alcohol tolerance may provide additional information on the safety and tolerability of medications to treat AUD, in particular, when novel medications are co-administered with alcohol within the AUD population. Conclusions As such, alcohol tolerance represents an additional outcome that may be included in randomized clinical trial (RCT) protocols designed for developing AUD pharmacotherapies.

Methods reporting in human laboratory studies

Addiction ◽  
2013 ◽  
Vol 108 (5) ◽  
pp. 1002-1003 ◽  
Author(s):  
Olivia M. Maynard ◽  
Marcus R. Munafò
Keyword(s):  
Laboratory Studies ◽  
Human Laboratory

scholarly journals Isradipine Decreases the Hemodynamic Response of Cocaine and MethamphetamineResults From Two Human Laboratory Studies

2005 ◽  
Vol 18 (6) ◽  
pp. 813-822 ◽  
Author(s):  
B JOHNSON ◽  
L WELLS ◽  
J ROACHE ◽  
C WALLACE ◽  
N AITDAOUD ◽  
...  
Keyword(s):  
Hemodynamic Response ◽  
Laboratory Studies ◽  
Human Laboratory

Human Laboratory Studies of Buprenorphine

1992 ◽  
Author(s):  
Jack H. Mendelson ◽  
Nancy K. Mello
Keyword(s):  
Laboratory Studies ◽  
Human Laboratory

scholarly journals Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies

2020 ◽  
Vol 23 (9) ◽  
pp. 559-570 ◽  
Author(s):  
Suhas Ganesh ◽  
Jose Cortes-Briones ◽  
Mohini Ranganathan ◽  
Rajiv Radhakrishnan ◽  
Patrick D Skosnik ◽  
...  
Keyword(s):  
Data Repository ◽  
Positive Symptoms ◽  
Laboratory Studies ◽  
Healthy Human ◽  
Syndrome Scale ◽  
Human Volunteers ◽  
Combining Data ◽  
Negative Syndrome ◽  
Psychotomimetic Effects ◽  
Human Laboratory

Abstract Introduction There is increasing interest in the relationship between cannabinoids and psychosis. While individual human laboratory studies have been critical in demonstrating that cannabinoids (e.g., delta-9-tetrahydrocannabinol [THC]) can induce acute transient psychosis-like effects in healthy human volunteers, combining data from multiple studies offers a fine-grained view of these effects. Methods THC-induced psychosis-relevant effects were examined using a data repository of 10 double-blind, randomized, placebo-controlled, crossover studies with 400 i.v. THC infusions in healthy human volunteers. The Positive and Negative Syndrome scale was used to measure psychotomimetic effects. The profile of symptoms, frequency of a response, its relationship to THC dose and substance use, latent structure in Positive and Negative Syndrome scale response, and the relationships between psychotomimetic and perceptual alteration symptoms were evaluated. Results Clinically meaningful increases in positive symptoms were noted in 44.75% infusions; conceptual disorganization, hallucinations, blunted affect, somatic concern, motor retardation, and poor attention were the items most frequently altered by THC. The increase in Positive and Negative Syndrome scale positive symptoms was positively associated with THC dose (beta = 11.13, SE = 4.94, Wald χ 2 = 19.88, P < .001) and negatively associated with frequent cannabis use (beta = −0.575, SE = 0.14, Wald χ 2 = 18.13, P < .001). Furthermore, positive symptoms were strongly correlated with Clinician Administered Dissociative States Scale perceptual alterations score (rs = 0.514, P < .001). Conclusion Intravenous administration of THC consistently induces psychotomimetic effects that include symptoms across Positive and Negative Syndrome scale domains. Moreover, healthy individuals who frequently use cannabis have a blunted psychotomimetic response.

Sign in / Sign up

Export Citation Format

Share Document